蛋白尿将肝硫酸乙酰肝素转化为PCSK9的有效结合伙伴
研究在大鼠模型中探索蛋白尿对PCSK9、肝脏硫酸乙酰肝素蛋白聚糖及血浆富甘油三酯残粒脂蛋白的影响。阿霉素注射大鼠出现蛋白尿、甘油三酯和总胆固醇升高,血清PCSK9与蛋白尿相关,肝硫酸乙酰肝素过度硫酸化增强PCSK9结合,可能损害残粒脂蛋白摄取而导致血脂异常。
要点
- 蛋白尿大鼠肝硫酸乙酰肝素过度硫酸化,增强PCSK9结合。
- 蛋白尿与血清PCSK9、甘油三酯和总胆固醇显著相关。
- PCSK9/硫酸乙酰肝素或为控制血脂异常的新靶点。
核心结论
- 蛋白尿诱导肝硫酸乙酰肝素蛋白聚糖过度硫酸化,增加对PCSK9的亲和力,可能损害肝脏富甘油三酯残粒脂蛋白摄取,导致蛋白尿相关血脂异常。
研究设计与样本
- 阿霉素注射大鼠蛋白尿模型,检测蛋白尿、血脂、PCSK9及肝脏硫酸乙酰肝素蛋白聚糖。
主要发现
- 蛋白尿大鼠出现蛋白尿、甘油三酯和总胆固醇显著升高。
- 蛋白尿与甘油三酯、总胆固醇及血清PCSK9显著相关,且低密度脂蛋白受体未见丢失。
- 蛋白尿大鼠PCSK9积聚于肝窦,对照组位于肝细胞胞质。
- 蛋白尿大鼠肝硫酸乙酰肝素侧链过度硫酸化,硫酸化是PCSK9结合的主要决定因素。
- PCSK9部分与过度硫酸化硫酸乙酰肝素共定位,仅见于蛋白尿大鼠。
临床怎么用
- 蛋白尿患者应关注血脂异常,尤其是高甘油三酯血症。
- PCSK9/硫酸乙酰肝素轴可能成为控制蛋白尿相关血脂异常的新靶点。
局限性
- 研究为阿霉素诱导的大鼠模型,结论需在人类中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatic uptake of triglyceride-rich remnant lipoproteins is mediated by the low-density lipoprotein receptor, a low-density lipoprotein receptor related protein and the heparan sulfate proteoglycan, syndecan-1. Heparan sulfate proteoglycan also mediates low-density lipoprotein receptor degradation by a regulator of cholesterol homeostasis, proprotein convertase subtilisin kexin type 9 (PCSK9), thereby hampering triglyceride-rich remnant lipoproteins uptake. In this study, we investigated the effects of proteinuria on PCSK9, hepatic heparan sulfate proteoglycan and plasma triglyceride-rich remnant lipoproteins. Adriamycin-injected rats developed proteinuria, elevated triglycerides and total cholesterol (all significantly increased). Proteinuria associated with triglycerides and total cholesterol and serum PCSK9 (all significant associations) without loss of the low-density lipoprotein receptor as evidenced by immunofluorescence staining and western blotting. In proteinuric rats, PCSK9 accumulated in sinusoids, whereas in control rats PCSK9 was localized in the cytoplasm of hepatocytes. Molecular profiling revealed that the heparan sulfate side chains of heparan sulfate proteoglycan to be hypersulfated in proteinuric rats. Competition assays revealed sulfation to be a major determinant for PCSK9 binding. PCSK9 partly colocalized with hypersulfated heparan sulfate in proteinuric rats, but not in control rats. Hence, proteinuria induces hypersulfated hepatic heparan sulfate proteoglycans, increasing their affinity to PCSK9. This might impair hepatic triglyceride-rich remnant lipoproteins uptake, causing proteinuria-associated dyslipidemia. Thus, our study reveals PCSK9/heparan sulfate may be a novel target to control dyslipidemia.
引用
- Shrestha P, Yazdani S, Vivès RR, et al. Proteinuria converts hepatic heparan sulfate to an effective proprotein convertase subtilisin kexin type 9 enzyme binding partner. Kidney Int. 2021. PMID: 33609572. doi:10.1016/j.kint.2021.01.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。